GrayMatters Health Achieves 10,000 Patient Sessions Milestone with Prism PTSD Treatment

GrayMatters Health Reaches a Significant Clinical Milestone

On February 9, 2026, GrayMatters Health (GMH) announced the remarkable achievement of conducting 10,000 patient sessions using their innovative Prism™ treatment designed for individuals coping with post-traumatic stress disorder (PTSD). This landmark session occurred at Breakthru Psychiatric Solutions, where patients benefit from GMH's digital brain biomarker technology.

Dr. Karen Giles, a psychiatrist and founder of the Georgia-based psychiatric practice, expressed her enthusiasm, stating that this milestone exemplifies not only the commitment to their patients but also the increasing accessibility of effective treatments for mental health challenges. The Prism system adopts a unique approach by specifically targeting the amygdala network, enabling patients to develop coping strategies for auto-responses associated with their mental health difficulties.

The Prism treatment integrates a patient-centered methodology, where individuals are guided to connect with calming personal memories or emotions. This process aids in moderating their biometric responses, displayed through a captivating simulation of animated characters who behave in response to the patient's calming experiences. The sophistication of this interactive model highlights how technology and psychology converge to foster therapeutic outcomes.

“This achievement represents the escalating confidence among mental health professionals regarding addressing the persistent treatment gaps in PTSD,” commented Kirk Thelander, Chief Commercial Officer of GrayMatters Health. He underscored that reaching such a critical milestone validates the effectiveness of their digital brain biomarkers as a customized and objective treatment paradigm. Increasingly, patients are finding tools for mental regulation that they can employ within clinical settings as well as their own lives.

In clinical studies, data illustrates that about 70% of participants dealing with PTSD demonstrated substantial symptom relief, and close to a third achieved complete remission post-treatment with Prism. The side effects associated with this pioneering intervention are typically mild and short-lived, allowing patients to quickly return to their daily activities without significant disruption.

GrayMatters Health is at the forefront of mental health solutions, leveraging digital fMRI-informed biomarkers to craft an interventional psychiatry suite that provides various treatment options. The pioneering Prism™ self-neuromodulation tool empowers patients to discover effective strategies for self-regulating the brain activity that contributes to their mental health disorders. Currently, Prism is FDA-cleared for treating PTSD, with initiatives underway to expand its applicability to other mental health conditions such as depression.

In collaboration with leading mental health institutions, GMH explores additional psychiatric disorders through rigorous research and evaluation of the Prism treatment. This commitment to advancing mental health technology reinforces their role as leaders in the industry.

For those interested in uncovering more about GrayMatters Health and the transformative Prism treatment, detailed information is available on their website at graymatters-health.com, along with updates and insights shared through their LinkedIn profile.

The rapid evolution and adoption of GMH’s Prism stands not only as a beacon of hope for those affected by PTSD but also as a leading model for the future of personalized mental healthcare.